(0.13%) 5 187.70 points
(0.08%) 38 884 points
(-0.10%) 16 333 points
(-0.20%) $78.22
(0.27%) $2.21
(-0.06%) $2 322.70
(-0.18%) $27.50
(0.27%) $991.10
(0.08%) $0.930
(0.22%) $10.92
(0.09%) $0.800
(0.02%) $91.46
5 days till quarter result
(bmo 2024-05-13)
Expected move: +/- 7.56%
2.55% $ 0.540
@ $0.735
Emitido: 14 feb 2024 @ 14:11
Retorno: -26.51%
Señal anterior: feb 13 - 15:21
Señal anterior:
Retorno: 6.03 %
Live Chart Being Loaded With Signals
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation...
Stats | |
---|---|
Volumen de hoy | 1.66M |
Volumen promedio | 2.36M |
Capitalización de mercado | 109.96M |
EPS | $0 ( 2024-03-13 ) |
Próxima fecha de ganancias | ( $-0.220 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.360 |
ATR14 | $0.00100 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-24 | Pooler Amy | Sell | 2 209 | Common Stock |
2024-02-25 | Pooler Amy | Sell | 2 459 | Common Stock |
2024-02-24 | Willoughby Scott B. | Sell | 4 379 | Common Stock |
2024-02-25 | Willoughby Scott B. | Sell | 3 453 | Common Stock |
2024-02-24 | Dubois-stringfellow Nathalie | Sell | 5 474 | Common Stock |
INSIDER POWER |
---|
3.18 |
Last 100 transactions |
Buy: 7 300 210 | Sell: 7 415 564 |
Volumen Correlación
Sangamo Therapeutics Inc Correlación
10 Correlaciones Más Positivas | |
---|---|
ISNS | 0.898 |
CYRN | 0.889 |
ENNV | 0.884 |
AMTX | 0.884 |
FBIZ | 0.874 |
UK | 0.873 |
ARVN | 0.87 |
CMCT | 0.869 |
CLNE | 0.869 |
FCBC | 0.867 |
10 Correlaciones Más Negativas | |
---|---|
BOCH | -0.891 |
ARDX | -0.869 |
CINC | -0.866 |
HEES | -0.86 |
STRL | -0.859 |
OSUR | -0.859 |
ATAK | -0.858 |
BCOR | -0.857 |
LRFC | -0.857 |
STAY | -0.857 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Sangamo Therapeutics Inc Correlación - Moneda/Commodity
Sangamo Therapeutics Inc Finanzas
Annual | 2023 |
Ingresos: | $176.23M |
Beneficio Bruto: | $154.04M (87.41 %) |
EPS: | $-1.480 |
FY | 2023 |
Ingresos: | $176.23M |
Beneficio Bruto: | $154.04M (87.41 %) |
EPS: | $-1.480 |
FY | 2022 |
Ingresos: | $111.30M |
Beneficio Bruto: | $99.19M (89.12 %) |
EPS: | $-1.250 |
FY | 2021 |
Ingresos: | $110.70M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-1.230 |
Financial Reports:
No articles found.
Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico